ClinicalTrials.Veeva

Menu

Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections

M

Methodist Health System

Status

Enrolling

Conditions

Streptococcus Pneumoniae

Treatments

Drug: pneumoniae bacteremia therapy

Study type

Observational

Funder types

Other

Identifiers

NCT06096025
026.PHA.2023.A

Details and patient eligibility

About

Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis. S. pneumoniae bacteremia ranks among the top 10 most common pathogens associated with bloodstream infections and correlates with high morbidity and mortality worldwide.

Full description

The Infectious Diseases Society of America (IDSA) guidelines for CAP management advocate for short courses of antibiotics for CAP treatment. However, it does not address duration of therapy for common CAP pathogens such as S. pneumoniae when associated with blood stream infections (BSI). 3

Currently, GP bacteremia duration of therapy typically ranges from 7 to 14 days based on IDSA guideline recommendations for Staphylococcus aureus bacteremia with no further definitive consensus.4 Additionally, lack of data and randomized clinical trials on the efficacy and safety of short compared to long treatment duration have led to variability in practice. Most randomized clinical trials as well as retrospective studies on treatment duration, have been conducted mainly in gram-negative BSI

Enrollment

200 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • • ≥18 years of age

    • S. pneumoniae isolated from ≥1 blood cultures
    • Active IV antibiotic therapy within 48 hours of the first positive blood culture(7,8)
    • Clinical stability by day 10 of therapy

Exclusion criteria

  • • Treatment duration <5 days or >16 days

    • Death before completion of therapy (<10 days vs. ≥ 10 days )
    • Polymicrobial BSI
    • Invasive infection caused by S. pneumoniae (endocarditis, meningitis, and lung abscess)

Trial contacts and locations

1

Loading...

Central trial contact

Colette Ngo Ndjom, MS; Bethany Brauer, MPH

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems